(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...

Enjaymo treats cold agglutinin disease, a condition in which the immune system attacks red blood cells and causes them to rupture. This process happens at cold temperatures, giving the disease its ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red ...